In the present study, we investigated whether the presence of thyroid autoimmunity alone and the level of thyroid peroxidase IgG autoantibodies may be helpful to predict the response to omalizumab in clinical practice, thus discriminating patients with probable severe type I or type IIb CSU. Here, TPO is linked to autoimmune thyroid disease.